YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지
DOI QR코드

DOI QR Code

Quantification of Globotriaosylsphingosine in Urine using UPLC-ESI-MS/MS; Application for Screening Fabry Disease

파브리병의 신속한 진단을 위한 소변 중 Globotriaosylsphingosine의 UPLC-ESI-MS/MS 분석법

  • Yoon, Hye-Ran (Biomedical & Pharmaceutical Analysis Lab., College of Pharmacy, Duksung Women's University)
  • 윤혜란 (덕성여자대학교 약학대학 생의약분석실)
  • Received : 2015.12.11
  • Accepted : 2016.02.22
  • Published : 2016.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Globotriaosylsphingosine (lyso Gb3) is considered as one of the biomarkers for Fabry disease. A rapid and simple UPLC-MS/MS method was developed for the determination of reliable biomarker, lyso Gb3. Total analytical procedure takes only 15 min including sample preparation and MS/MS analysis. Limit of detection was 0.85 ng/ml (S/N=3). The calibration curve was linear over the range of 2.0~400.0 ng/ml ($R^2=0.9999$). Inter-day and intra-day assay accuracy were 93.4~100.6% (RSD, 0.6~6.0%) and 97.5~100.7% (RSD, 3.6~5.2%). Absolute recoveries of 97.6~98.6 showed excellence of a new analytical method. The method was applied to human and mice urines, proved the suitability for the quantification of lyso-Gb3 for screening, diagnosis and therapeutic monitoring of Fabry disease patients.

Keywords

References

  1. Scriver, C. R., Sly, W. A., Beaudet, A. L. and Valle, D. : The metabolic and molecular bases of inherited disease, ed.. McGraw Hill, New York (2001).
  2. Wilcox, W. R., Oliveira, J. P., Hopkin, R. J., Ortiz, A., Banikazemi, M., Rasmussen, U. F., Sims, K., Waldek, S., Pastores, G. M., Lee, P., Eng, C. M., Marodi, S., Standford, K. E., Breunig, F., Wanner, C., Warnock, D. G., Lemay, R. M. and Germain, D. P. : Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol. Genet. Metab. 93, 112 (2008). https://doi.org/10.1016/j.ymgme.2007.09.013
  3. Whitfield, D. P., Calvin, J., Hogg, S., O'Driscoll, E., Halsall, D., Burling, K., Maguire, G., Wright, N., Cox, T. M., Meikle, P. J. and Deegan, P. B. : Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 28, 21 (2005). https://doi.org/10.1007/s10545-005-4415-x
  4. Kitagawa, T., Ishige, N., Suzuki, K., Owada, M., Ohashi, T., Kobayashi, M., Eto, Y., Tanaka, A., Mills, K., Winchester, B. and Keutzer, J. : Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol. Genet. Metab. 85, 196 (2005). https://doi.org/10.1016/j.ymgme.2005.01.007
  5. Rozenfeld, P. A., De Francesco, N. P., Borrajo, G. J., Ceci, R. and Fossati, C. A. : An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring. Clin. Chim. Acta. 403, 194 (2009). https://doi.org/10.1016/j.cca.2009.02.016
  6. Rombach, S. M., Dekker, N., Bouwman, M. G., Linthorst, G. E., Zwinderman, A. H., Wijburg, F. A., Kuiper, S., vd Bergh Weerman, M. A., Groener, J. E. M., Poorthuis, B. J., Hollak, C. E. M. and Aerts, J. M. : Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim. Biophys. Acta. 1802, 741 (2010). https://doi.org/10.1016/j.bbadis.2010.05.003
  7. Scheidt, W. V., Eng, C. M., Fitzmaurice, T. F., Erdmann, E., Hubner, G., Olsen, E. G., Christomanou, H., Kandolf, R. and Esnick, R. J. : An atypical variant of Fabry's disease with manifestations confined to the myocardium. N. Engl. J. Med. 324, 395 (1991). https://doi.org/10.1056/NEJM199102073240607
  8. Kusano, E., Saito, O., Akimoto, T. and Asano, Y. : Fabry disease: experience of screening dialysis patients for Fabry disease. Clin. Exp. Nephro. 18, 273 (2014).
  9. Gold, H., Mirzaian, M., Dekker, N., Ferraz, M. J., Lugtenburg, J., Codee, J. D., Marel, G. A., Overkleeft, H. S., Linthorst, G. E., Groener, J. E., Aerts, J. M. and Poorthuis, B. J. : Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin. Chem. 59, 547 (2013). https://doi.org/10.1373/clinchem.2012.192138
  10. Togawa, T., Kodama, T., Suzuki, T., Sugarawa, K., Tsukimura, T., Ohashi, T., Ishige, N. and Suzuki, K. : Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol. Genet. Metab. 100, 257 (2010). https://doi.org/10.1016/j.ymgme.2010.03.020
  11. Aerts, J. M., Groener, J. E., Kuiper., Doncker-Koopman, W. E., Strijland, A., Ottenhoff, R., Van Roomen, C., Mirzaian, M., Wijburg, F. A., Linthorst, G. E., Vedder, A. C., Rombach, S. M., Cox-Brinkman, J., Somerharju, P., Bootr, G., Hollak, C. E., Brady, R. O. and Poorthuis, B. J. : Proc. Natl. Acad. Sci. USA 105, 2812 (2008). https://doi.org/10.1073/pnas.0712309105
  12. Clarke, J. T. : Narrative review: Fabry disease. Ann. Intern. Med. 146, 425 (2007). https://doi.org/10.7326/0003-4819-146-6-200703200-00007
  13. Lavoie, P., Boutin, M. and Auray-Blais, C. : Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. Anal. Chem. 85, 1743 (2013). https://doi.org/10.1021/ac303033v
  14. Young-Gqamana, B., Brignol, N., Chang, H. H., Khanna, R., Soska, R., Fuller, M., Sitaraman, S. A., Germain, D. P., Giugliani, R., Hughes, D. A., Mehta, A., Nicholls, K., Boudes, P., Lockhart, D. J., Valenzano, K. J. and Benjamin, E. R. : Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS One, doi:10.1371/journal.pone.0057631 Epub (2013).
  15. Auray-Blais, C., Ntwari, A., Clarke, J. T. R., Warnock, D. G., Paulo Oliveira, J., Young, S. P., Millington, D. S., Bichet, D. G., Sirrs, S., West, M. L., Casey, R., Hwa, W. L., Keutzer, J. M., Zhang, X. K. and Gagnon, R. : How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?. Clin. Chim. Acta. 411, 1906 (2010). https://doi.org/10.1016/j.cca.2010.07.038
  16. Boutin, M. and Auray-Blias, C. : Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb3-related analogues in Fabry disease. Anal. Chem. 86, 3476 (2014). https://doi.org/10.1021/ac404000d
  17. Dupont, F. O., Gagnon, R., Boutin, M. and Auray-Blais, C. : A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers. Curr. Med. Chem. 20, 280 (2013). https://doi.org/10.2174/092986713804806685
  18. Auray-Blais, C., Blais, C. M., Ramaswami, U., Boutin, M., Germain, D. P., Dyack, S., Bodamer, O., Morell, G. P., Clarke, J. T., Bichet, D. G., Warnock, D. G., Echevarria, L., West, M. L. and Lavoie, P. : Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin. Chem. Acta. 438, 195 (2015). https://doi.org/10.1016/j.cca.2014.08.002
  19. Johnson, B., Mascher, H., Mascher, D., Legnini, E., Hung, C. Y., Dajnoki, A., Chein, Y. H., Marodi, L., Hwa, W. L. and Bodamer, O. A. : Analysis of lyso-globotriaosylsphingosine in dried blood spots. Ann. Lab. Med. 33, 274 (2013). https://doi.org/10.3343/alm.2013.33.4.274
  20. Food and drug administration http://www.fda.gov/downloads/Drugs/.../Guidances/ ucm070107.pdf (2001).
  21. Causon, R. : Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J. Chromatogr. B. Biomed. Sci. Appl. 689, 175 (1997). https://doi.org/10.1016/S0378-4347(96)00297-6
  22. Kruger, R., Tholey, A., Jakoby, T., Vogelsberger, R., Monnikes, R., Rossmann, H., Beck, M. and Lacker, K. J. : Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry. J. Chromatogr. B. 833, 128 (2012).
  23. Young, E., Mills, K., Morris, P., Vellodi, A., Lee, P., Waldek, S. and Winchester, B. : Is globotriaosylceramide a useful biomarker in Fabry disease? Acta. Paediatr. 94, 51 (2005). https://doi.org/10.1080/08035320510028111
  24. Fan, J. Q. and Ishii, S. : Cell-based screening of active-site specific chaperone for the treatment of Fabry disease. Methods Enzymol. 363, 412 (2003).
  25. Fan, J. Q., Ishii, S., Asano, N. and Suzuki, Y. : Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat. Med. 5, 112 (1999). https://doi.org/10.1038/4801
  26. Valenzano, K. J., Khanna, R., Powe, A. C., Boyd, R. and Lee, G. : Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev. Technol. 9, 213 (2011). https://doi.org/10.1089/adt.2011.0370
  27. Togawa, T., Kawashimab, I., Kodamaa, T., Tsukimurra, T., Suzukia, T., Fukushuged, T., Kanekurad, T. and Sakurabaa, H. : Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease. Biochim. Biophys. Acta. 399, 716 (2010).